Glaxosmithkline Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• Glaxosmithkline Pharmaceuticals Ltd reported a 19.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 3.0%.
• Its expenses for the quarter were up by 16.2% QoQ and down 6.2% YoY.
• The net profit increased 25.6% QoQ and increased 2.0% YoY.
• The earnings per share (EPS) of Glaxosmithkline Pharmaceuticals Ltd stood at 15.2 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Glaxosmithkline Pharmaceuticals Ltd is a leading entity in the pharmaceutical industry, primarily involved in the research, development, and manufacture of prescription medicines. It operates in a competitive market, focusing on various therapeutic areas, including respiratory, oncology, and vaccines. The company is part of the global GlaxoSmithKline group, a major player in the healthcare sector. Recent developments in the pharmaceutical industry, such as advancements in biotechnology and personalized medicine, continue to shape the business landscape in which Glaxosmithkline Pharmaceuticals operates. However, specific recent developments related directly to the company were not available in the provided information.

Revenue

In Q2FY26, Glaxosmithkline Pharmaceuticals Ltd reported a total income of ₹1013.51 crores, marking a 19.4% increase from the previous quarter (Q1FY26) where the total income was ₹848.89 crores. This indicates a strong quarter-over-quarter growth in revenue. Year-over-year, the total income saw a slight decline of 3.0% compared to Q2FY25, when it was ₹1045.31 crores. The company's revenue performance demonstrates notable quarter-over-quarter growth, although there has been a slight year-over-year decline which warrants close monitoring to understand underlying factors.

Profitability

The company achieved a profit before tax of ₹354.00 crores in Q2FY26, which represents a 26.9% increase from ₹278.98 crores recorded in Q1FY26. Comparatively, this is a 3.0% increase from the ₹343.81 crores reported in Q2FY25. The tax expense for Q2FY26 was ₹96.51 crores, which is 30.5% higher than the previous quarter and 5.7% higher year-over-year. Consequently, profit after tax was ₹257.49 crores in Q2FY26, reflecting a 25.6% increase from Q1FY26 and a 2.0% increase from Q2FY25. The earnings per share for the quarter stood at ₹15.20, up by 25.6% quarter-over-quarter and 1.9% year-over-year.

Operating Metrics

Total expenses for Q2FY26 amounted to ₹662.15 crores, which is a 16.2% increase from the preceding quarter's ₹569.91 crores but a 6.2% decrease from the ₹706.19 crores recorded in the same quarter of the previous year. This indicates a reduction in year-over-year expenses despite the quarter-over-quarter rise. The company's operating performance shows an ability to manage expenses effectively on a year-over-year basis, contributing to the overall profitability. Key financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio were not provided in the data, thus restricting a more detailed financial ratio analysis.